Catalent Inc.

Company Overview

Catalent is a significant player in CDMO services, delivering distinctive development and manufacturing solutions across diverse therapeutic categories, including drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. The company’s extensive capabilities encompass oral, injectable, and respiratory delivery technologies, complemented by cutting-edge protein, plasmid, viral, and cell and gene therapy manufacturing capacities.

Till 2021, Catalent’s operational framework comprised four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. However, at the year-end of 2022, the company underwent a significant organizational change, transitioning to a new operating structure characterized by two primary segments. These two segments are now identified as (1) Biologics and (2) Pharma and Consumer Health. The biologics segment products are focused on biopharmaceuticals (Catalent Inc, 2022). In contrast, the Pharma and Consumer Health segment emphasizes Catalent’s engagement in pharmaceutical and consumer health products, encapsulating a more streamlined and strategic approach to its diverse business activities.

The company specialized in providing comprehensive development and manufacturing services across various therapeutic modalities within the Biologics segment. This includes expertise in handling proteins, plasmid DNA (pDNA), messenger RNA (mRNA), cell therapy, viral vaccines, and gene therapies based on viral vectors. The company also offers formulation, development, and manufacturing of parenteral dose forms, such as vials, prefilled syringes, cartridges, analytical development, and testing services tailored for large molecules.

Financial Highlights (FY 2023)

Company's Business Segments

• Biologics : "This segment offers formulation, development, and manufacturing for biologic proteins, cell genes, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, vaccines; formulation, development, and manufacturing for parenteral dose forms, such as vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules."
• Pharma and Consumer Health : This segment provides market-leading capabilities for complicated oral solids, soft gel formulations, Zydis fast dissolve technologies, gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, topical dose forms; clinical trial development and supply services.